Last $49.53 USD
Change Today +3.39 / 7.35%
Volume 698.3K
NLNK On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

newlink genetics corp (NLNK) Snapshot

Open
$45.95
Previous Close
$46.14
Day High
$49.71
Day Low
$44.68
52 Week High
03/4/15 - $49.71
52 Week Low
10/13/14 - $17.32
Market Cap
1.4B
Average Volume 10 Days
494.1K
EPS TTM
$3.19
Shares Outstanding
28.0M
EX-Date
--
P/E TM
15.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEWLINK GENETICS CORP (NLNK)

newlink genetics corp (NLNK) Details

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer. Its portfolio includes biologic product candidates based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2,3)-dioxygenase (IDO) pathway. The company’s lead product candidate, HyperAcute Pancreas immunotherapy that is being studied in Phase III clinical trials in surgically-resected pancreatic cancer patients, as well as in patients with advanced pancreatic cancer. It is also developing HyperAcute Lung immunotherapy for non-small cell lung cancer; HyperAcute Melanoma immunotherapy for the treatment of patients with advanced melanoma; and HyperAcute Renal cell cancer immunotherapy product candidate, as well as HyperAcute prostate cancer and HyperAcute breast cancer immunotherapy product candidates. In addition, the company is developing IDO pathway inhibitors comprising indoximod, a small-molecule, orally bioavailable product candidate, which is being studies in metastatic breast cancer, as well as a therapy after sipuleucel-T treatment in metastatic castrate-resistant prostate cancer; and NLG919 for patients with solid tumors. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

newlink genetics corp (NLNK) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $540.8K
President, Chief Operations Officer and Chief...
Total Annual Compensation: $420.0K
Clinical & Regulatory Compliance Officer and ...
Total Annual Compensation: $283.8K
Vice President of Business Development
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2013.

newlink genetics corp (NLNK) Key Developments

NewLink Genetics Corporation Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

NewLink Genetics Corporation announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of $169,245,000 compared to $294,000 for the same period a year ago. Income from operations was $149,030,000 compared to loss from operations of $7,913,000 for the same period a year ago. Income before taxes was $149,043,000 compared to loss before taxes of $7,916,000 for the same period a year ago. Net income was $126,855,000 compared to net loss of $8,046,000 for the same period a year ago. Net earnings per diluted share were $4.05 compared to net loss per diluted share of $0.31 for the same period a year ago. For the year, the company announced total revenue of $172,592,000 compared to $1,093,000 for the same period a year ago. Income from operations was $117,573,000 compared to loss from operations of $31,141,000 for the same period a year ago. Net income before taxes was $117,633,000 compared to loss before taxes of $31,050,000 for the same period a year ago. Net income was $102,858,000 compared to net loss of $31,180,000 for the same period a year ago. Net earnings per diluted share were $3.32 compared to net loss per diluted share of $1.23 for the same period a year ago.

NewLink Genetics Corporation to Receive $20 Million in Connection with License and Collaboration Agreement with Merck

NewLink Genetics Corporation announced that it had received notification from Merck that the event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV (Ebola) vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20 million in connection with the achievement of the event. The event pertains to the initiation of a key clinical trial for the vaccine. The rVSV-EBOV vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC), and licensed by BioProtection Systems Inc. PHAC will be entitled to a payment from NewLink Genetics in connection with this event.

NewLink Genetics Corporation to Report Q4, 2014 Results on Feb 26, 2015

NewLink Genetics Corporation announced that they will report Q4, 2014 results at 12:00 PM, GMT Standard Time on Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NLNK:US $49.53 USD +3.39

NLNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NLNK.
View Industry Companies
 

Industry Analysis

NLNK

Industry Average

Valuation NLNK Industry Range
Price/Earnings 13.9x
Price/Sales 7.5x
Price/Book 6.3x
Price/Cash Flow 12.6x
TEV/Sales 6.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWLINK GENETICS CORP, please visit www.newlinkgenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.